Clinical Trials Unit

Medicine & Life Sciences

1. Africa South of the Sahara 21%
2. African Trypanosomiasis 11%
3. Antimony Sodium Gluconate 8%
4. artemisinine 18%
5. Artesunate 17%
6. artesunate drug combination amodiaquine 12%
7. Bacterial Vaginosis 23%
8. Belgium 44%
9. Biomass 8%
10. Blood Culture 8%
11. Burkholderia pseudomallei 9%
12. Burkina Faso 24%
13. Cambodia 17%
14. CD4 Lymphocyte Count 11%
15. Child 13%
16. Clinical Trials 24%
17. Cohort Studies 28%
18. Coinfection 15%
19. Condoms 9%
20. Confidence Intervals 10%
21. Contraceptive Agents 12%
22. Cross-Sectional Studies 11%
23. Democratic Republic of the Congo 20%
24. dihydroartemisinin 12%
25. Disease Outbreaks 9%
26. Dysbiosis 8%
27. Eastern Africa 11%
28. Ebola Hemorrhagic Fever 14%
29. Enzyme-Linked Immunosorbent Assay 10%
30. Epidemiology 8%
31. Ethical Review 11%
32. Ethics Committees 8%
33. Ethiopia 33%
34. Female Contraceptive Devices 20%
35. Fever 8%
36. Gambia 16%
37. Gardnerella vaginalis 12%
38. Ghana 10%
39. Gonorrhea 13%
40. Guinea 24%
41. Health 9%
42. Hepatitis C 17%
43. HIV 100%
44. HIV Infections 18%
45. HIV-1 8%
46. Human Herpesvirus 2 8%
47. Immune Reconstitution Inflammatory Syndrome 18%
48. Incidence 10%
49. Income 9%
50. India 9%
51. Infection 19%
52. Informed Consent 20%
53. Kenya 28%
54. Lactobacillus 14%
55. Leishmania 9%
56. Leishmania donovani 8%
57. Leishmaniasis 10%
58. Literacy 11%
59. Lumefantrine Drug Combination Artemether 12%
60. Malaria 46%
61. Mefloquine 11%
62. Microbiota 18%
63. miltefosine 10%
64. Mortality 9%
65. Mouthwashes 8%
66. Multimedia 9%
67. Neisseria gonorrhoeae 15%
68. Odds Ratio 10%
69. Pentamidine 9%
70. piperaquine 13%
71. Placebos 10%
72. Polymerase Chain Reaction 10%
73. Population 22%
74. Pre-Exposure Prophylaxis 36%
75. Prednisone 10%
76. Pregnancy 10%
77. Pregnant Women 11%
78. Rabies 12%
79. Randomized Controlled Trials 10%
80. Retrospective Studies 15%
81. Risk-Taking 11%
82. Routine Diagnostic Tests 13%
83. Rwanda 17%
84. Safe Sex 9%
85. Safety 16%
86. Senegal 10%
87. Sex Workers 9%
88. Sexual and Gender Minorities 23%
89. Sexual Behavior 14%
90. Sexual Partners 9%
91. Sexually Transmitted Diseases 37%
92. South Africa 19%
93. Syphilis 23%
94. Tanzania 12%
95. Therapeutics 19%
96. Tuberculosis 18%
97. Uganda 12%
98. Viral Load 11%
99. Visceral Leishmaniasis 58%
100. Zambia 11%